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Abstract
BACKGROUND: Traditional large-scale culture systems for human mesenchymal stem/stromal cells (hMSCs) use solid microcar-
riers as attachment substrates. Although the use of such substrates is advantageous because of the high surface-to-volume
ratio, cell harvest from the same substrates is a challenge as it requires enzymatic treatment, often combined with agitation.
Here, we investigated a two-phase system for expansion and non-enzymatic recovery of hMSCs. Perfluorocarbon droplets were
dispersed in a protein-rich growth medium and were used as temporary liquid microcarriers for hMSC culture.
RESULTS: hMSCs successfully attached to these liquid microcarriers, exhibiting similar morphologies to those cultured on solid
ones. Fold increases of 3.03 ± 0.98 (hMSC1) and 3.81 ± 0.29 (hMSC2) were achieved on day 9. However, the maximum expan-
sion folds were recorded on day 4 (4.79 ± 0.47 (hMSC1) and 4.856 ± 0.7 (hMSC2)). This decreasewas caused by cell aggregation
upon reaching confluency due to the contraction of the interface between the two phases. Cell quality, as assessed by differen-
tiation, cell surface marker expression and clonogenic ability, was retained post expansion on the liquid microcarriers. Cell har-
vesting was achieved non-enzymatically in two steps: first by inducing droplet coalescence and then aspirating the interface.
Quality characteristics of hMSCs continued to be retained even after inducing droplet coalescence.
CONCLUSION: The prospect of a temporary microcarrier that can be used to expand cells and then ‘disappear’ for cell release
without using proteolytic enzymes is a very exciting one. Here, we have demonstrated that hMSCs can attach and proliferate
on these perfluorocarbon liquid microcarriers while, very importantly, retaining their quality.
© 2020 The Authors. Journal of Chemical Technology and Biotechnology published by John Wiley & Sons Ltd on behalf of
Society of Chemical Industry (SCI).
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INTRODUCTION
Human mesenchymal stem/stromal cells (hMSCs) are attractive
candidates for large-scale allogeneic therapy for multiple reasons:
their availability in adults, relatively easy isolation from a variety of
tissues, potential to differentiate to multiple cell types (adipo-
cytes, osteocytes and chondrocytes), low immunogenicity and
ability to induce regeneration by various mechanisms including
exosomes and secretion of paracrine factors.1,2 To date, hMSCs
have been successfully cultured using attachment substrates such
as microcarriers, which are usually solid particles, ~200–300 μm in
size, made of a variety of materials, to provide a large surface area
for growth and thus the potential for scale-up rather than scale-
out;3 i.e., microcarriers allow hMSC cultures to be translated from
traditional T-flasks to bioreactor platforms. hMSCs have also been
grown in both serum-based and serum-free media and at scales
ranging from 15 mL in high-throughput bioreactor platforms4 to
spinner flasks,5–9 bench litre-scale stirred tank reactors (STR)10,11
and even up to 50 L.12
The microcarrier concept was first introduced by van Wezel in
1967, who used modified dextran.13 There are currently a variety
of commercially available microcarriers with different surface
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chemistries to fulfil the needs of many types of cells. Microcarriers
include those with the core made of alginate (GEM; Global Cell
Solutions), collagen (CultiSpher G and S; Percell, Åstorp, Sweden),
dextran (Cytodex 1 and 3; GE Healthcare, Chalfont St Giles, UK) or
polystyrene (plastic, collagen, Hillex, ProNectin etc.; Pall SoloHill,
Bingham Farms, MI, USA).14 The core material, surface properties
and particle size are all important factors that influence cell adhe-
sion and proliferation on such substrates. Thus commercially
available microcarriers come in different sizes, with or without
protein coating and with or without surface charge,15,16 covering
a wide range of applications and cell types. They also differ in
porosity and density, which are important aspects to take into
consideration when designing a bioprocess and planning the
cell-harvesting procedure.
Since hMSCs themselves are typically the product of a culture,
particularly if intended for clinical use, they need to be detached
and separated from the attachment substrate. In static planar con-
ditions, this process is simple as it comprises one step alone,
namely the incubation of the cells with a proteolytic enzyme such
as trypsin.7 However, in stirred bioreactors with microcarriers, har-
vesting is more complex. It involves two steps: first, cell detach-
ment from the microcarriers to produce a cell–microcarrier
suspension; and, second, a cell separation step to separate the
cells from the microcarriers. Cell detachment from microcarriers
just by enzymatic means proved inefficient in spinner flasks and
had to be combined with agitation,17 with the cell separation
from microcarriers being achieved by filtration. Subsequently,
the detachment technique was applied to other stirred bioreac-
tors and microcarriers.18 To date, this approach has continued to
work well,19 but there is always the possibility with some donor
cells that such agitation may impact cell yield or quality. The over-
all approach increases in complexity with the increase in scale,
and nothing has been published to substantiate its effectiveness
at scale. In addition, there are concerns that enzymatic treatments
for cell harvest could result in proteome alterations,20 which can
raise safety issues when using cells for therapies. As such, a non-
enzymatic harvesting procedure would be preferable and it is that
topic which this paper addresses.
Non-enzymatic approaches for cell harvest from microcarriers
have previously been investigated by utilising specifically
designed microcarriers such as temperature-responsive21–23 or
dissolvable24 ones. Temperature-responsive microcarriers are
capable of non-enzymatic cell harvest by manipulating the cul-
ture temperature, which determines a gradual change in hydro-
philicity, leading to a gradual cell release. Although this
approach has some advantages, it requires engraftment of the
temperature-responsive polymer on existing microcarriers, which
needs specialist knowledge and/or equipment. In addition, care-
ful consideration of the impact of the required culture tempera-
ture change on cell quality is necessary.
Another type of such microcarrier is dissolvable and uses mod-
ified hydrogels, but they still require a specific enzymatic treat-
ment to dissolve the microcarrier and thus to release the cells
without breaking the bonds proteolytically. Rodrigues et al. tested
the Corning dissolvable microcarriers and found them successful
at expanding induced pluripotent stem cells, but more impor-
tantly at recovering them from the microcarriers with a 92% har-
vesting yield.24 However, the Corning dissolvable microcarriers
have now been discontinued, which means that preparation of
such microcarriers again requires specific skills and expertise.
The concept of a temporary microcarrier based on an immisci-
ble oil phase in an agitated STR is an exciting prospect that could
address all of these challenges and result in a simplified biopro-
cess. It would allow for cell expansion on the drops generated
by stirring and, when required at the end of the expansion phase,
cell harvest could be achieved non-enzymatically by inducing
droplet coalescence. If coalescence resulted in cell accumulation
at the interface between the two phases, it should be possible
to readily collect the cells from it by centrifugation or aspiration
(Fig. 1). Thus this technology would not require either a detach-
ment or a filtration step for separation of microcarriers, resulting
in a simplified bioprocess. The temporary liquid microcarrier con-
cept explored here comprised a two-phase system of a selected
perfluorocarbon (Fluorinert FC40) and protein-rich growth
medium. This system was previously tested in a planar set-up
and found successful for the expansion of hMSCs, while retaining
cell quality.25 Moreover, the prospect of recycling the perfluoro-
carbon was also tested in our previous study,25 with no significant
difference found in cell expansion on fresh or recycled perfluoro-
carbon. This finding is important as it is anticipated that recycling
the perfluorocarbon, particularly at large scales, could lead to a
reduction of cost associated with the use of substrates for cell
attachment.
MATERIALS AND METHODS
Monolayer expansion of hMSCs
Two hMSCs, referred to here as hMSC1 and hMSC2, were isolated
from bone marrow aspirates (Lonza, Cologne, Germany) from two
healthy donors after informed consent. For all experiments,
Figure 1. Schematic for the production of temporary microcarriers. The perfluorocarbon is mixed with growth medium to form a dispersion of stable
liquid perfluorocarbon droplets that can be used as temporary microcarriers. The cells can be inoculated and expanded on to these liquid microcarriers.
When harvest is required, coalescence of the droplets is induced, resulting in phase separationwith accumulation of cells at the interface, fromwhere they
can be readily collected. The perfluorocarbon can then be recovered and recycled.25
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hMSCs between passages 2–6 were used. The cells were cultured
according to previously determined protocols.7,25 Briefly, the cells
were seeded at 5000 cells cm−2 and cultured on tissue culture
plastic in growth medium comprising DMEM (1 g L−1 glucose,
Lonza) supplemented with 10% (v/v) foetal bovine serum
(HyClone, Thermo Fisher, Waltham, MA, USA) and 2 mmol L−1
UltraGlutamine (Lonza, Castleford, UK). Growth medium was
replaced every 3 days and the cells were passaged every 6 days
when 70–80% confluency was achieved. Cell subculture was done
by incubating with 0.25% (w/w) trypsin/EDTA for 7 min at 37 °C in
a humidified incubator. The enzyme was then inactivated by the
addition of pre-warmed growth medium and the cell suspension
was centrifuged at 220 × g for 5 min at room temperature. The
obtained cell pellet was then resuspended in a known volume
of medium for cell counts and further processing.
Preparation of liquid microcarriers
The perfluorocarbon selected for preparing the liquid microcarriers
was Fluorinert FC40 (3M, Sigma Aldrich, UK). This perfluorocarbon
was found to promote attachment and proliferation of hMSCs, while
retaining their quality post expansionwhenused as a 2Dplanar culture
system.25 To prepare the liquidmicrocarriers, an emulsion of Fluorinert
FC40 perfluorocarbon and growth medium was made by mixing the
two components. Initially, the perfluorocarbon was sterilised by
autoclaving at 121 °C and 2 atm for 15 min. For all experiments, ultra-
low attachment well plates (Corning, Hawarden, UK) were used to
ensure cell attachment was only achieved on the liquid microcarriers
and not on the tissue culture plastic. For the preparation of liquid
microcarriers, pre-sterilised perfluorocarbon needs to be dispersed in
the growth medium (containing serum). This dispersion could be
achieved by mixing, using various methods including an impeller
directly in the bioreactor vessel.26 In this study, because of the small
quantities needed, the dispersion of perfluorocarbon in serum-
containing medium was done by vortexing for 30 s (SciQuip vortex
mixer). A 1:5 perfluorocarbon-to-growth medium ratio (equivalent of
a 16.7% volume fraction) was used to prepare the liquid microcarriers.
Dropletswith ameandiameter (d0.5) of 292 μmanda spanvaluebelow
1 were produced (Table 1). Span values of less than the unity are con-
sidered uniform size distributions.27,28 Prior to cell inoculation, the liq-
uid microcarriers were conditioned in growth medium for at least 1 h
at 37 °C and 5% CO2 in a humidified incubator to allow proteins from
the serum present in the medium to deposit onto the liquid microcar-
riers to promote cell attachment and proliferation.
Cell culture on the temporary liquid microcarriers
The equivalent of 12 cm2 of interfacial surface area provided by
the liquid droplets was inoculated into each well in ultralow
attachment well plates (Corning). The interfacial surface area per
volume of emulsion was calculated using Eqns (1) and (2) below:
Interfacial areaper volume
=
6*Volume fraction of dispersed phase
d32
m2m−3
  ð1Þ
Volume fraction of dispersed phase=
Vi
Vtotal
ð2Þ
where d32 represents the Sauter diameter [m
3 m−2], Vi is the vol-
ume of dispersed phase [m3] and Vtotal is the total volume of dis-
persion produced in one batch [m3]. The Sauter diameter was
obtained by measuring the droplet size and volumetric size distri-
bution using a laser diffraction particle analyser (Mastersizer 2000,
Malvern Instruments, Great Malvern, UK).
The hMSCs were inoculated on to the liquid microcarriers at
10 000 cells cm−2 of interfacial area and were kept in culture for
up to 6 days. To avoid removing liquid microcarriers and attached
cells, an 80% medium exchange was performed every 2 days.
Experiments were performed under static conditions only and in
ultra-low attachment well plates. The well plates were kept in a
humidified incubator at 37 °C and 5% CO2.
Cell harvest
The perfluorocarbon droplets dispersed in the protein-richmedium
were found to be highly stable even though no stabilising reagents
(e.g. surfactants) were added. This stability was investigated in one
of our previous studies,26 where we hypothesised that it is caused
by the proteins present in the media. Similarly, another hypothesis
was that by removing the proteins present through repeated
washes the droplets would then be destabilised and coalescence
would be induced26 to release the cells. To test that hypothesis,
the cells cultured on the liquid microcarriers were harvested by
two methods: (i) by incubating with 0.25% trypsin–EDTA at 37 °C
and 5% CO2 for 7 min in a humidified incubator; or (ii) by inducing
droplet coalescence through repeated washes with Dulbecco's
phosphate-buffered saline (D-PBS) (without calcium and magne-
sium), leading to non-enzymatic cell release and accumulation to
the interface, from where the cells were then collected by aspira-
tion using a sterile Pasteur pipette. The cell pellet was then
obtained by centrifugation at 220 × g for 5 min.
Cell characterisation
hMSCs were characterised before and after expansion on the liq-
uid microcarriers and after harvest by differentiation towards the
three lineages (adipogenic, osteogenic and chondrogenic), by
assessing clonogenic potential, by multiparameter flow cytome-
try to assess the expression of a panel of five cell surface markers
and by sandwich ELISA to measure production of selected pro-
angiogenic growth factors. Cells cultured on tissue culture poly-
styrene (TCPS) were used as controls.
Trilineage differentiation
All chemicals were purchased from Sigma Aldrich unless other-
wise stated. hMSCs were differentiated towards adipogenic, oste-
ogenic and chondrogenic lineages using StemPro differentiation
kits (Thermo Fisher). A 12-well plate was used for all experiments.
hMSCs were seeded at 5000 cells cm−2 for osteogenic differentia-
tion and 10 000 cells cm−2 for adipogenic differentiation. For
chondrogenic differentiation, the micromass method was used.7
Table 1. Perfluorocarbon/DMEM emulsion droplet size analysis based on volumetric size distribution
Perfluorocarbon-to-growth medium ratio D(0.1)/μm D(0.5)/μm D(0.9)/μm D(3.2)/μm Span
1:5 191.73 292.62 444.36 277.45 0.863
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Briefly, 5 μL droplets of a highly concentrated cell suspension
(1 × 107 cells mL−1) were seeded in an empty well plate and
allowed to attach for 1–2 h at 37 °C in an incubator. Upon cell
attachment, chondrogenic differentiation medium (StemPro)
was added. For all differentiation cultures, the cells were grown
in their respective media for 21 days, with a medium change per-
formed every 3–4 days. At the end of 21 days, the cells were fixed
with 4% paraformaldehyde for 20 min at room temperature. Adi-
pocytes were stainedwith 0.3% (v/v) Oil Red O in 99% isopropanol
for 10min at room temperature, followed by two washes with dis-
tilled water. Chondrocytes were stained with 1% (v/v) Alcian Blue
in 0.1 mol L−1 HCl solution for 60 min. Osteogenic differentiation
potential was assessed using von Kossa stain, as previously
described.25 Briefly, the cells were first stained for alkaline phos-
phatase (ALP) at room temperature in the dark for 45 min, fol-
lowed by silver nitrate incubation at room temperature in the
presence of light for 30 min to stain bone mineralisation. Imaging
was carried out on a Nikon Ti Eclipse phase contrast microscope.
Clonogenic potential
Two hundred and fifty cells were inoculated into growth medium
in a T25 flask. A minimum of five flasks were inoculated and
placed in a humidified incubator set at 37 °C and 5% CO2. The
medium was changed every 3–4 days and the culture was carried
out for up to 14 days. The colonies were fixed and stainedwith 1%
crystal violet (Sigma Aldrich, UK) for 30 min at room temperature
and thenmanually counted. Colony-forming unit fibroblast (CFU-f).
efficiency was calculated using Eqn (3):
CFU−f efficiency=
Number of colonies counted
Number of cells seeded
×100 %½  ð3Þ
Immune-phenotype assessment
The immune-phenotype of the hMSCs used was assessed by
multi-parameter flow cytometry using a previously developed
protocol.29 Briefly, the cells were harvested from the substrate
as described previously and counted, and the cell suspension
was concentrated to achieve a concentration of 1 × 106
cells mL−1. 200 μL of cell suspension was then loaded on to a V-
bottom 96-well plate and centrifuged at 220 × g for 5 min. The
supernatant was aspirated, and the cell pellet was resuspended
in cell staining buffer (R&D Systems, Abingdon, UK) and centri-
fuged again. The cells were stained with mouse anti-human
monoclonal antibodies (BD Biosciences, Swindon, UK) for 30 min
in the dark at room temperature. The fluorescently labelled anti-
bodies were selected based on a panel recommended by the
International Society for Cell Therapy (ISCT);30 these were CD73
(PE-Cy7), CD90 (APC), CD105 (PE), CD34 (PE-Cy5) and HLA-DR
(FITC). The stained samples were analysed on a Guava EasyCyte
8HT flow cytometer (Merck Millipore, Watford, UK) equipped with
488 nm and 640 nm excitation lasers. A minimum of 10 000 gated
events were recorded for each sample. Post-acquisition analysis
and compensation were performed using FlowJo software v8
(Treestar Inc., Meza, AZ, USA).
Assessment of pro-angiogenic growth factors secretion profile
Conditioned medium from hMSCs cultured on TCPS and on liquid
microcarriers at different time points in culture was collected and
analysed using themultiplex assay Luminex Magpix kits (R&D Sys-
tems) according to the manufacturer's instructions. The kits were
customised to include the following factors: IL8, basic fibroblast
growth factor (bFGF), hepatocyte growth factor (HGF), vascular
endothelial growth factor (VEGF) and platelet-derived growth fac-
tor (PDGF-AA). Standards were prepared by reconstituting a pre-
mixed cocktail. Capture microparticle cocktail was added to
each well of a 96-well assay plate. Samples or standards prepared
in triplicate were added to each well, sealed in foil and incubated
for 2 h at room temperature on an orbital shaker. The plate was
washed three times, incubated with biotin antibody cocktail for
1 h at room temperature, then washed and incubated with
streptavidin–phycoerythrin for a further 30 min. Beads were cap-
tured and analysed using a BioPlex Magpix Multiplex reader. Array
data were quantified using BioPlex Data Pro software.
Analytical techniques
Droplet size and volumetric size distribution weremeasured using
a Mastersizer 2000 (Malvern Instruments) laser diffraction particle
analyser. The polydispersity of the droplet sizes was calculated as
the span, which is the width of distribution based on 10%, 50%
and 90% of the cumulative distribution of sizes:
Span=
D 0:9ð Þ−D 0:1ð Þ
D 0:5ð Þ ð4Þ
<NI>where D(0.1), D(0.5) and D(0.9) are droplet sizes at which
10%, 50% and 90%, respectively, of the volume distribution lies
on the cumulative curve.
Cell morphology was assessed by phase contrast on a Nikon Ti
Eclipse microscope. Cell counts were performed using a Nucleo-
counter NC-3000 (Chemometec) directly on the liquid microcar-
riers using the reagent A100 and reagent B protocol. Briefly, the
cell–microcarrier suspension was diluted in a 1:3 ratio with
reagent A100 (lysing agent) and then reagent B (stabilising agent).
The resulting suspension was then loaded onto a Via-1 cassette
containing acridine orange and DAPI.
Based on cell counts, the fold increase was calculated using the
equation below:
FI=
Cx fð Þ
Cx 0ð Þ ð5Þ
<NI>where Cx(f ) represents the maximum cell number and Cx
(0) is the initial cell number.
Statistical analysis
All experiments were performed in triplicate as a minimum. Cell
counts for every time point were acquired from two independent
samples from each replicate. Data were expressed as mean ± SD.
Statistical analysis was carried out using GraphPad Prism 8 soft-
ware. For comparison between two data sets, statistical signifi-
cance was determined by using Student's two-tailed t-test. For
comparison of multiple data sets, significance was calculated by
the one-way or two-way ANOVA test. Significance was deter-
mined at P < 0.05.
RESULTS AND DISCUSSION
The aim of this work was to show that: (i) perfluorocarbon droplets
could be used as liquid microcarriers for the expansion of hMSCs;
(ii) non-enzymatic cell harvest could be achieved (i.e., test the
temporary microcarrier concept); and (iii) the cells retained their
quality attributes both post-expansion and post-droplet coales-
cence (allow a non-enzymatic cell harvest).
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Expansion of hMSCs on the liquid microcarriers
A size range comparable to commercially available solid microcar-
riers was provided by the 1:5 ratio (16.7% volume fraction) of
perfluorocarbon-to-growth medium. As such, this formulation
was taken forward to be tested as temporary liquid microcarriers
for the growth of hMSCs. A previous study in planar culture25
showed that hMSCs were able to attach and proliferate at the
interface between the same perfluorocarbon (Fluorinert FC40)
and growth medium, while exhibiting a similar cell morphology
to hMSC cultured on TCPS. Moreover, the same study demon-
strated that hMSCs retained their ability to differentiate towards
the three lineages, their clonogenicity potential and expression
of cell surface markers. As such, a similar behaviour was expected
when inoculating hMSCs on to the liquid perfluorocarbon
microcarriers.
Cell morphology was visually assessed. Figure 2(A) shows
hMSC2 donor line morphology when cultured on TCPS, while
Fig. 2(B) shows the morphology of the same donor hMSC line
when cultured on the perfluorocarbon/growth medium interface
in a planar set-up. Microcarriers are curved surfaces and, as a
result, cell morphology can appear slightly different to that on pla-
nar surfaces. A transparent microcarrier (e.g., Cytodex 1, GE
Healthcare) (Fig. 2C) was chosen to enable a better visualisation
of cell morphology for comparison to the liquid microcarriers
(Fig. 2D). Elongated cell morphologies, typical to hMSCs, were
observed on both types of microcarriers – solid (Fig. 2C) and liquid
(Fig. 2D), as indicated by the white arrows.
Two hMSC donor lines (hMSC1 and hMSC2) were cultured for
a period of 9 days on the liquid microcarriers (Fig. 3A). An
increase in cell number was recorded up to day 4 in culture;
however, beyond this point, a decrease was observed. As the
cells grew and occupied more of the surface area of each liquid
microcarrier, the protein layer deposited on the interface
between the two phases became stretched, thus resulting in
altering the shape of the liquid microcarriers from spherical
to tear-shaped droplets (Fig. 3B). Moreover, as the cells grow,
with conventional microcarriers, the tendency is for cells to
form bridges between them.9 However, on the liquid microcar-
riers, bridging resulted in formation of cell aggregates at the
centre of a droplet bouquet as indicated in Fig. 3(B) by the
white arrow. The formation of the droplet ‘bouquet’ was
observed only after 4 days, indicating that confluency on some
microcarriers was achieved at that time point, while others had
barely any cells attached. These experiments were carried out
under static conditions, which explains the heterogenic distri-
bution of cells on the liquid microcarriers. Moreover, a high cell
seeding density (10 000 cells cm−2) was used for inoculation
that was two times higher than the seeding density used on
solid microcarriers in our previous studies.4,6,9 A lower cell
seeding density could result in confluency being reached more
slowly and an overall increase in fold expansion being
achieved. However, this study was only a proof-of-concept
demonstration and not an optimised expansion bioprocess.
Live/dead staining showed the maintenance of cell viability,
with an increase in dead cells towards the later stages of cul-
ture (day 6) localised in the centre of the aggregates formed
(Fig. 3B). The formation of aggregates and the reaching of con-
fluency can explain the decrease in cell number from day 4 to
day 9 of culture (Fig. 3A). A sharper decrease of approximately
50% in cell number was observed for hMSC1 donor line, com-
pared to only approximately 10% for hMSC2 donor line. This
difference could be attributed to donor-to-donor variability.7
The growth of the same hMSC2 donor line was measured over
time in culture on both the 2D planar and liquid microcarriers
formed with Fluorinert FC40 and growth medium. When com-
pared, cell growth on the liquid microcarriers achieved a fold
increase normalised to the surface area of 3.81 ± 0.25 at day
9, while 3.83 ± 1.41 at day 10 was achieved on the planar
Figure 2. hMSCmorphology when cultured on: (A) tissue culture plastic; (B) 2D perfluorocarbon/DMEM system; (C) commercially available microcarriers
(e.g., Cytodex-1); and (D) perfluorocarbon ‘liquidmicrocarriers’. Scale bar represents, in (A) and (B), 500 μm; and, in (C) and (D), 100 μm.White arrows show
the elongated shape of hMSCs on the Cytodex solid microcarriers (C) and the perfluorocarbon liquid microcarriers (D).
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interface (2D). However, the highest normalised fold increase on
the liquid microcarriers was achieved at day 4 (4.86 ± 0.61)
(Fig. 3C). After this time point, a decrease in cell number was
recorded similarly to Fig. 3(A) andmost likely for the same reasons.
The improved growth on liquid microcarriers in a proof-of-concept
demonstration is highly promising as the production of large num-
bers of stem cells on an immiscible liquid planar surface suffers
from the same limitations as growth in standard T-flasks.
Figure 3. (A) Fold increase over 9 days in static culture on liquid microcarriers for two hMSC lines; data are expressed as mean ± SD (n = 4). (B) Phase
contrast and live/dead merged images of hMSCs on liquid microcarriers at day 2 and day 6 in culture. Scale bars represent 100 μm. (C) Normalised fold
increase over time in culture for hMSC2 donor line when cultured on either the 2D or the 3D perfluorocarbon/DMEM system; data are shown as mean
± SD (n = 4).
Figure 4. hMSC2 donor line quality assessment post expansion on the liquid microcarriers. (A) Cell morphology after replating on TCPS; scale bar repre-
sents 500 μm. (B) Differentiation to the three lineages before and after culture on liquid microcarriers; scale bars for adipogenic images 100 μm, and for
osteogenic images 500 μm. (C) CFU-f efficiency; data are shown as mean ± SD (n = 5; ****P < 0.0001).
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Cell quality assessment pre and post expansion on liquid
microcarriers
Cell exposure to the culture environment in a stirred bioreac-
tor may have a detrimental effect on cell quality. As such, cell
characterisation needs to be performed before and after bio-
processing to ensure that none of the steps taken impacts cell
quality negatively. Guidelines for hMSC characterisation were
previously published by Dominici et al. and included replating
on TCPS, differentiation towards three lineages (adipogenic,
osteogenic and chondrogenic), clonogenicity assessment
and cell surface marker expression.30 For assessing cell quality
post expansion on the liquid microcarriers, the cells were har-
vested initially by enzymatic means. Figure 4(A) shows hMSC2
donor line morphology after replating on TCPS. Figure 4(B)
shows the differentiation potential before and after culture
on the liquid microcarriers. Differentiation to adipocytes was
deemed successful both pre and post culture on the liquid
microcarriers due to the presence of lipid vesicles stained in
red, which are typical of adipocytes.31 Differentiation to osteo-
genic lineage was also deemed successful, as bone mineralisa-
tion was visibly stained in black, while alkaline phosphatase
expression, which is specific to osteocytes,32 was evident
through the red staining. Similarly, chondrogenic differentia-
tion was successful as micromasses were formed and stained
in blue, indicating strong formation of glycosaminoglycans
representative of cartilage.33 Clonogenicity potential was also
assessed before and after expansion on liquid microcarriers
(Fig. 4C). CFU-f efficiency was found to be significantly lower
post expansion (****P < 0.0001). However that difference
could be attributed to the increase in cell passage number. A
panel of five cell surface markers was assessed by flow cytome-
try. Figure 5(A) shows the cell surface marker expression
before expansion and Fig. 5(B) after expansion on the liquid
microcarriers. In both scenarios, expression of CD73, CD90
and CD105 was above 97% positive, while expression of
CD34 and HLA-DR was below 2% positive. Post expansion on
the liquid microcarriers, this expression profile was retained
(Fig. 5B).
There are many physiological processes that hMSCs are believed
to influence through paracrine effects.34,35 Angiogenesis is one
such process. Pro-angiogenesis growth factors secretion was
assessed before (when cultured on TCPS) and after culture of
hMSC2 donor line on the liquid microcarriers (Fig. 5C). There was
a significant difference (**P < 0.001) between the interleukin-8
(IL-8) levels per cell produced by the hMSC2 donor line at day
6 when cultured on TCPS (0.943 ± 0.09 fg mL−1 per cell) compared
to the liquid microcarriers (0.602 ± 0.05 fg mL−1 per cell) (Fig. 5C).
IL-8 is a key factor in capillary tube organisation, while promoting
higher proliferation rates of epithelial cells.36 The higher IL-8 levels
per cell produced when the cells were cultured on TCPS could indi-
cate an increased capacity to form capillary tubes and an increased
proliferation rate on that substrate. The former has not been veri-
fied here. However, the lower IL8 levels correlate with a lower pro-
liferation rate when cultured on liquid microcarriers. Thus, it could
be hypothesised that these lower levels are linked to the formation
of aggregates towards the later stages of culture (Fig. 3).
VEGF is another factor that was measured here and it is a potent
mediator of angiogenesis, known to induce growth of blood vessels
and to stimulate migration of endothelial cells.37 VEGF was produced
in similar levels regardless of the substrate used (P > 0.05) (Fig. 5C).
HGF is a regulator of cell growth, motility and morphogenesis,38
and it has also been found to stimulate the expression of a number
of other growth factors and receptors, including VEGF.35, 39 No levels
of HGF (0 ± 0 fg mL−1 per cell) were measured on TCPS, but some
HGF (0.463 ± 0.231 fg mL−1 per cell) was recorded when cultured
on liquid microcarriers. However, the amount was not significant
Figure 5. Multiparameter flow cytometry assessment of hMSC2 donor
line expression of CD73, CD90, CD105, HLA-DR and CD34 (A) pre-
expansion (TCPS) and (B) post-expansion on the liquid microcarriers.
(C) Pro-angiogenic growth factor profile per cell at day 6 in culture for
hMSC2 donor line cultured on TCPS and liquid microcarriers. Data are
shown as mean ± SD (n = 3; **P < 0.001; ns, non-significant.
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(P > 0.05) (Fig. 5C). Here, the VEGF level at day 6 was not significantly
different (P > 0.05) on any of the tested substrates, despite the
increased level of HGF on liquid microcarriers.
bFGF was alsomeasured. It is known to act similarly to VEGF and
to mediate proliferation, migration and differentiation of epithe-
lial cells.40 There was no significant difference (P > 0.05) in the
bFGF levels produced by the hMSC donor line 2 at day 6 when cul-
tured on TCPS or the liquid microcarriers (Fig. 5C). However, the
bFGF levels were slightly lower on liquid microcarriers (0.307
± 0.019 fg mL−1 per cell) compared to TCPS (0.498
± 0.12 fg mL−1 per cell). It is worth noting that this result was
somewhat expected as, at the end of hMSC culture on the liquid
Figure 6. Multiparameter flow cytometry assessment of hMSC2 donor line expression of CD73, CD90, CD105, HLA-DR and CD34: (A) before and (B) after
inducing coalescence of liquid microcarriers.
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microcarriers (Fig. 3A), there was a decrease in cell number caused
by the formation of cell aggregates due to the contraction of the
interface between the two phases, which produced a decreased
cell proliferative rate.
Non-enzymatic cell harvest assessment
The dispersions produced with the FC40 perfluorocarbon and
growth medium were found to be stable for at least 5 days when
stored at 4 °C, which was unexpected given that surfactants were
not used within the formulation. Only after 5 days of storage,
some signs of droplet coalescence were observed. Surfactants
are typically used to produce stabilised dispersions of very fine
drops (emulsions). Here, the drops in these stabilised dispersions
are rather large compared to those typically found in emulsions.
However, it can be hypothesised that the increased stability of
the perfluorocarbon droplets was determined by the steric stabi-
lisation caused by the proteins found in serum. Proteins are
amphiphilic molecules and have been used before for stabilising
oil-in-water emulsions.41 The hypothesis is that, once absorbed on
to the interface, protein unfolding takes place, thus leading to the
hydrophilic groups protruding into the aqueous phase (e.g., growth
medium), resulting in droplet stabilisation by steric interactions. This
hypothesis was tested and confirmed in our previous study.26 In that
study, although perfluorocarbon droplet coalescence could not be
achieved under dynamic conditions, it was successful when static,
combined with multiple D-PBS washes. Here, static coalescence was
exploited to establish non-enzymatic cell harvest.
After four consecutive D-PBS washes, complete droplet coales-
cence was achieved, which resulted in separation of the two
phases and accumulation of the released cells to the interface,
from where they were collected by aspiration with a sterile Pas-
teur pipette. The harvested cells were characterised and the
results are shown in Figs 6 and 7. Post coalescence, the cells
retained the high expression of CD73, CD90 and CD105 (>93%),
while only a small proportion of cells (<3%) were HLA-DR and
CD34 positive (Fig. 6B). This expression was comparable to that
seen pre coalescence (Fig. 6A). Differentiation potential towards
the three lineages – adipogenic (Fig. 7A), osteogenic (Fig. 7B)
and chondrogenic (Fig. 7C) – was retained post-droplet coales-
cence. CFU-f efficiency was found to be significantly higher
(**P < 0.001) post-droplet coalescence than by means of enzy-
matic harvesting from the liquid droplets (Fig. 7D). Non-enzymatic
means for harvesting cells from substrates such as temporary liq-
uid microcarriers could be highly advantageous for the previously
mentioned reasons and could lead to simplified manufacturing
processes for cells for therapies.
CONCLUSIONS
The prospect of a temporary microcarrier that can allow cell
expansion and, when required at the end of culture, permit non-
enzymatic cell harvest, is an exciting one. This study describes
the use of such temporary microcarriers represented by stable
perfluorocarbon droplets dispersed in a serum-based cell culture
medium. These liquid microcarriers can be produced in situ in
Figure 7. Differentiation post-inducing coalescence of liquid microcarriers: (A) adipogenic; scale bar represents 100 μm; (B) osteogenic; scale bar repre-
sents 500 μm; (C) chondrogenic; scale bar represents 100 μm; (D) CFU-f efficiency. Data are shown as mean ± SD (n = 5).
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the bioreactor at any scale by applying mixing to break down the
perfluorocarbon into droplets and disperse them in the medium.
The proteins present in serum will then stabilise these droplets
and, at the same time, condition them for cell culture. This is a sim-
ple and inexpensive system that can be tailored to the needs of
culture. The mixing applied and ratio of perfluorocarbon-to-
medium will dictate the size and size distribution of the liquid
microcarriers.
In this study, hMSCs were used to test the suitability of the liquid
microcarriers for culture. However, this approach could potentially
be suitable for the culture of any adherent cell type. When tested
with hMSCs, the cells successfully attached and grew on the liquid
microcarriers, while, very importantly, retaining their quality post
expansion and post non-enzymatic harvest, achieved by inducing
droplet coalescence through simple steps such as washes.
This study was carried out in a serum-basedmedium. However, the
manufacture of clinically relevant hMSCs for therapy will require the
use of serum-free and xeno-free media. To overcome this challenge,
our proposed liquid microcarriers could still be prepared in alterna-
tives to serum such as human platelet lysate, which is still protein rich
and could be used in the formulation of the two-phase system with-
out affecting the stability of the liquid microcarriers.
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